The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market is characterized by extremely high therapeutic costs, making pharmacoeconomic analysis—the study of cost-effectiveness—critical for healthcare systems. The choice between delivery methods for Immunoglobulin (Ig) is a major cost driver.

• Ig as the Primary Cost Driver: For both Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIg), the cost of the drug itself constitutes the vast majority (often over 85%) of the total annual treatment cost per patient.

• SCIg Cost-Saving Potential: Numerous cost-minimization analyses (particularly from the societal perspective) suggest that SCIg can be cost-saving compared to IVIG, despite the similar drug cost. These savings accrue from reduced non-health care costs (patient/caregiver time and travel) and health care system costs (significantly less nursing time, no need for dedicated hospital infusion centers, and reduced risk of systemic adverse events requiring subsequent treatment).

• Reimbursement Challenges: The high cost of Ig products means reimbursement approval is a complex, often centralized process, creating a critical market access challenge for all Ig-based therapies, as detailed in specialized health economic reports, such as the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Outlook.